Squarepoint’s Sonoma Pharmaceuticals SNOA Stock Holding History

Squarepoint’s Portfolio SNOA Stock Details SNOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-786	Closed	-$88K	–	3490
2021 Q3	$88K	Buy	+786	New	+$96.8K	﹤0.01%	2694

Other funds holding SNOA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HFS

HBC Financial Services Seattle, Washington $163M AUM 14.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Squarepoint's SNOA Position: Q4 2021 in Review

Squarepoint sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2021, closing a stake of 786 shares — an estimated $88K sold.

Squarepoint first reported a position in SNOA in Q3 2021 and held it in 1 quarter. The position peaked at $88K in Q3 2021. 18 funds tracked by Wall St. Rank hold SNOA as of Q4 2021.

Squarepoint reported no remaining Sonoma Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Squarepoint sold 786 Sonoma Pharmaceuticals shares in Q4 2021, an estimated $88K.
Squarepoint first reported a position in Sonoma Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Squarepoint's Sonoma Pharmaceuticals position peaked at $88K in Q3 2021.
18 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.